Literature DB >> 7509324

Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250.

H Uemura1, E Okajima, F M Debruyne, E Oosterwijk.   

Abstract

The potential usefulness of internal-image anti-idiotype antibodies (Ab2s) in modulating hosts' immune responses to tumor-associated antigen (TAA) have stimulated considerable interest in the development and characterization of Ab2s. Six different mouse monoclonal Ab2s (NUH31, 44, 51, 71, 82 and 91) were generated against murine monoclonal antibody G250 (MAbG250) which recognizes a human renal-cell carcinoma-associated antigen. All 6 Ab2s showed specificity for the MAbG250 paratope in Western-blot analysis. In inhibition assays, all Ab2s were able to compete with the nominal antigen, albeit with differing efficiency. Based on cross-blocking studies for idiotope mapping, the Ab2s could be divided into 2 groups (group I; NUH31, 51, 71, group 2; NUH44, 82, 91). However, cross-reactivity between these 2 groups was observed, indicating that they recognized partly overlapping epitopes on the paratope of MAbG250. Sera from rabbits immunized with Ab2s showed reactivity with G250 antigen-positive cell lysates, but not with antigen-negative cell lysates. Additional studies revealed that all Ab2s were able to induce anti-anti-idiotype antibodies resembling MAbG250 (Ab1'). These findings suggest that the Ab2s functionally mimic the original G250 antigen and may be of use in the immunotherapy of human renal-cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509324     DOI: 10.1002/ijc.2910560424

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.

Authors:  Cor H J Lamers; Sabine van Steenbergen-Langeveld; Mandy van Brakel; Corrien M Groot-van Ruijven; Pascal M M L van Elzakker; Brigitte van Krimpen; Stefan Sleijfer; Reno Debets
Journal:  Hum Gene Ther Methods       Date:  2014-12       Impact factor: 2.396

2.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors:  Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

3.  A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.

Authors:  Ian D Davis; Zhanqi Liu; Wayne Saunders; Fook-Thean Lee; Violeta Spirkoska; Wendie Hopkins; Fiona E Smyth; Geoffrey Chong; Anthony T Papenfuss; Bridget Chappell; Aurora Poon; Timothy H Saunder; Eric W Hoffman; Lloyd J Old; Andrew M Scott
Journal:  Cancer Immun       Date:  2007-08-17

4.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.

Authors:  H Uemura; Y Nakagawa; K Yoshida; S Saga; K Yoshikawa; Y Hirao; E Oosterwijk
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

5.  T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.

Authors:  Mamoru Harada; Yuichi Iida; Hitoshi Kotani; Takafumi Minami; Yoshihiro Komohara; Masatoshi Eto; Kazuhiro Yoshikawa; Hirotsugu Uemura
Journal:  Cancer Immunol Immunother       Date:  2021-06-23       Impact factor: 6.968

6.  Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer.

Authors:  Marc C Smaldone; David Yt Chen; Jian Q Yu; Elizabeth R Plimack
Journal:  Biologics       Date:  2012-11-19

7.  A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

Authors:  I Bleumer; A Knuth; E Oosterwijk; R Hofmann; Z Varga; C Lamers; W Kruit; S Melchior; C Mala; S Ullrich; P De Mulder; P F A Mulders; J Beck
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.